IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction

Benjamin W. Van Tassell, Cory R. Trankle, Justin M. Canada, Salvatore Carbone, Leo Buckley, Dinesh Kadariya, Marco G. Del Buono, Hayley Billingsley, George Wohlford, Michele Viscusi, Claudia Oddi-Erdle, Nayef A. Abouzaki, Dave Dixon, Giuseppe Biondi-Zoccai, Ross Arena, Antonio Abbate

Research output: Contribution to journalArticle

Abstract

Background Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was to determine whether IL (interleukin)-1 blockade with anakinra improved cardiorespiratory fitness in heart failure with preserved ejection fraction. Methods and Results Thirty-one patients with heart failure with preserved ejection fraction and CRP (C-reactive protein) >2 mg/L were randomized to anakinra (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. We measured peak oxygen consumption (Vo2), ventilatory efficiency (VE/Vco2 slope), and high-sensitivity CRP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 4, 12, and 24 weeks. Twenty-eight patients completed ≥2 visits, 18 women (64%), 27 (96%) obese. There were no differences in peak Vo2 or VE/Vco2 slope between groups at baseline. Peak Vo2 was not changed after 12 weeks of anakinra (from 13.6 [11.8-18.0] to 14.2 [11.2-18.5] mL·kg-1·min-1, P=0.89), or placebo (14.9 [11.7-17.2] to 15.0 [13.8-16.9] mL·kg-1·min-1, P=0.40), without significant between-group differences in changes at 12 weeks (-0.4 [95% CI, -2.2 to +1.4], P=0.64). VE/Vco2 slope was also unchanged with anakinra (from 28.3 [27.2-33.0] to 30.5 [26.3-32.8], P=0.97) or placebo (from 31.6 [27.3-36.9] to 31.2 [27.8-33.4], P=0.78), without significant between-group differences in changes at 12 weeks (+1.2 [95% CI, -1.8 to +4.3], P=0.97). Within the anakinra-treated patients, high-sensitivity CRP and NT-proBNP levels were lower at 4 weeks compared with baseline ( P=0.026 and P=0.022 versus placebo [between-group analysis], respectively). Conclusions Treatment with anakinra for 12 weeks failed to improve peak Vo2 and VE/Vco2 slope in a group of obese heart failure with preserved ejection fraction patients. The favorable trends in high-sensitivity CRP and NT-proBNP with anakinra deserve exploration in future studies. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02173548.

Original languageEnglish
Pages (from-to)e005036
JournalCirculation. Heart failure
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Keywords

  • cardiorespiratory fitness
  • exercise test
  • heart failure
  • inflammation
  • interleukin-1
  • natriuretic peptides
  • oxygen consumption

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction'. Together they form a unique fingerprint.

  • Cite this

    Van Tassell, B. W., Trankle, C. R., Canada, J. M., Carbone, S., Buckley, L., Kadariya, D., Del Buono, M. G., Billingsley, H., Wohlford, G., Viscusi, M., Oddi-Erdle, C., Abouzaki, N. A., Dixon, D., Biondi-Zoccai, G., Arena, R., & Abbate, A. (2018). IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circulation. Heart failure, 11(8), e005036. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005036